Chronic idiopathic urticaria

This study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…

This trial asks whether adding a Mediterranean diet or a low-histamine diet to standard care can reduce disease activity and improve quality of life in teens aged 12-18 with chronic spontaneous urticaria (CSU), a condition causing persistent hives. Participants are randomly assig…

This early-stage trial tests a single oral dose of HRS-3095, a new drug for chronic spontaneous urticaria (chronic hives), in 36 healthy adults. The main goal is to check safety and how the drug moves through the body. Results will guide future studies in patients with hives.

This study follows 470 adults with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will track how well it controls symptoms and any side effects over two years in real-world clinics. The goal is to see if remibrutinib works as well out…

This study tests an injection called JYB1904 in 180 adults with chronic spontaneous urticaria (hives and itching lasting over 6 weeks) that isn't well controlled by standard antihistamines. Participants receive either the drug or a placebo every 12 weeks for 48 weeks. The main go…

This study tests an experimental drug called BBT001 in adults with chronic spontaneous urticaria, a condition causing frequent hives without a clear trigger. Participants receive multiple doses of BBT001 or a placebo to see if it is safe and helps control symptoms. The trial focu…

This study tracks 350 people with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will survey patients and their doctors to see how well the drug controls symptoms and how satisfied patients are. The goal is to understand real-world ef…

This study tests an experimental pill called ICP-332 in 344 adults with moderate to severe chronic spontaneous urticaria (hives) that antihistamines can't control. Participants will take the drug or a placebo for 12 or 24 weeks. The main goal is to see if the drug reduces itching…

This study follows about 3,280 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls their hives in everyday medical practice. Participants either continue standard antihistamines or switch to remibrutinib, and researchers track symptom control and…

This study tests a new drug called lesigercept in 150 adults with chronic spontaneous urticaria (hives lasting 6+ months) that aren't controlled by standard antihistamines. Participants receive either lesigercept or a placebo injection. The main goal is to see if lesigercept redu…

This Phase 2 trial tests an injectable biologic called CM512 in 48 adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines. Participants are randomly assigned to receive either CM512 or a placebo shot, an…

This study is observing 225 adults with severe allergic asthma or chronic hives who are already doing well on the original omalizumab drug. Their doctors have decided to switch them to a biosimilar version called Omlyclo. The main goal is to see if they stay well-controlled for 1…

This study follows about 500 adults with chronic spontaneous urticaria (CSU) who are either starting remibrutinib or sticking with standard antihistamines. Researchers will track how well the drug controls hives and itching over 24 months, and monitor for side effects. The goal i…

This program provides remibrutinib, an experimental drug, to adults with chronic spontaneous urticaria (long-term hives) that haven't improved with antihistamines or omalizumab. Participants take the drug as prescribed to help control their symptoms. The goal is to offer access t…

This study looks at whether people with chronic spontaneous urticaria (long-term hives) who are well-controlled on omalizumab every 4 weeks can switch to every 6 weeks without losing control. Forty adults will be randomly assigned to continue standard dosing or extend their injec…

This study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate f…

This early-stage trial tested an experimental oral drug called BGB-16673 in 34 adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching. The study was double-blind and placebo-controlled, meaning neither patients nor doctors knew who got t…

This study tests a new daily pill (remibrutinib) against a standard injected drug (dupilumab) for adults with chronic hives that antihistamines can't control. About 400 participants will take either the pill or get the shot for 4 weeks to see which works faster. The goal is to re…

This study tests an experimental daily pill, ritlecitinib, for adults with chronic spontaneous urticaria (long-term itchy hives and swelling) that antihistamines don't fully control. About 200 participants will receive either 50 mg, 100 mg, or a placebo for 12 weeks, then all wil…

This early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this stu…

This study aims to find biological markers (biomarkers) that can help diagnose and monitor chronic induced urticaria (CIndU), a condition where specific triggers like cold or pressure cause itchy hives or swelling. Researchers will compare 40 participants—including people with CI…

This study looks at different forms of IgE (a protein involved in allergic reactions) in healthy volunteers and people with conditions like severe allergies, chronic hives, mastocytosis, and immune deficiencies. Researchers aim to understand how these IgE variations relate to hea…